Dr. Terashima on Future of Bursectomy and Omentectomy for Gastric Cancer

Masanori Terashima, MD, PhD, FACS
Published: Tuesday, Feb 14, 2017



Masanori Terashima, MD, PhD, FACS, Shizuoka Cancer Center, chairman of the Japanese Clinical Oncology Group, discusses the future of bursectomy and omentectomy for patients with gastric cancer.

The role of bursectomy has been controversial for many years, explains Terashima. Bursectomy is not beneficial to overall survival in patients with gastric cancer to make gastro-omentectomy become a standard of care.

Laparoscopic and robotic gastrectomy is becoming increasingly more popular as well, but both are risky and complicated procedures, says Terashima. Further research is needed to make these treatments safer for patients.
 


Masanori Terashima, MD, PhD, FACS, Shizuoka Cancer Center, chairman of the Japanese Clinical Oncology Group, discusses the future of bursectomy and omentectomy for patients with gastric cancer.

The role of bursectomy has been controversial for many years, explains Terashima. Bursectomy is not beneficial to overall survival in patients with gastric cancer to make gastro-omentectomy become a standard of care.

Laparoscopic and robotic gastrectomy is becoming increasingly more popular as well, but both are risky and complicated procedures, says Terashima. Further research is needed to make these treatments safer for patients.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Medical Crossfire®: Bridging Emerging Data to Advance Treatment Planning for Hepatocellular Carcinoma: A Multidisciplinary Tumor BoardMar 31, 20182.0
Publication Bottom Border
Border Publication
x